Page 6,651«..1020..6,6506,6516,6526,653..6,6606,670..»

Oriola-KD Corporation's Interim Report for 1 January – 30 June 2012

Posted: Published on July 26th, 2012

Oriola-KD Corporation Stock Exchange Release 26 July 2012 at 8.30 a.m. Key figures for 1 January - 30 June 2012 Net sales increased by 10.8 per cent to EUR 1,180.6 million (1-6/2011: EUR 1,065.6 million). Operating profit was EUR 9.7 million (1-6/2011: operating loss EUR 29.4 million including an EUR 33.4 million impairment charge related to the Russian Stary Lekar brand and operating profit excluding impairment charge EUR 4.0 million). Net cash flow from operations was EUR -8.1 million (1-6/2011: EUR -16.1 million). Net profit was EUR 3.2 million (1-6/2011: EUR -27.5 million) and earnings per share were EUR 0.02 (1-6/2011: EUR -0.18). Return on equity was 2.2 per cent (1-6/2011: -16.8 per cent). Outlook for 2012 is unchanged: Oriola-KD`s net sales are expected to increase 10-15 per cent and operating profit excluding one-off items is expected to come to EUR 23-33 million in 2012. Key figures for 1 April - 30 June 2012 Net sales increased by 10.1 per cent to EUR 589.7 million (4-6/2011: EUR 535.5 million). Read this article: Oriola-KD Corporation's Interim Report for 1 January - 30 June 2012 … Continue reading →

Posted in Wholesale Pharmacy | Comments Off on Oriola-KD Corporation's Interim Report for 1 January – 30 June 2012

Many synthetic drugs remain legal despite 'bath salts' ban

Posted: Published on July 26th, 2012

WASHINGTON -- People are inventing so many new ways to get high that lawmakers can't seem to keep up. Over the past two years, the U.S. has seen a surge in the use of synthetic drugs made of legal chemicals that mimic the dangerous effects of cocaine, amphetamines and other illegal stimulants. The drugs are often sold at small, independent stores in misleading packaging that suggests common household items like bath salts, incense and plant food. But the substances inside are powerful, mind-altering drugs that have been linked to bizarre and violent behavior across the country. Law enforcement officials refer to the drugs collectively as "bath salts," though they have nothing in common with the fragrant toiletries used to moisturize skin. President Barack Obama signed a bill into law earlier this month that bans the sale, production and possession of more than two dozen of the most common bath salt drugs. But health professionals say lawmakers cannot keep pace with bath salt producers, who constantly adjust their chemical formulations to come up with new synthetic drugs that aren't covered by new laws. Experts who have studied the problem estimate there are more than 100 different bath salt chemicals in circulation. … Continue reading →

Posted in Drugs | Comments Off on Many synthetic drugs remain legal despite 'bath salts' ban

Fewer teens using illegal drugs

Posted: Published on July 26th, 2012

26 July 2012 Last updated at 06:49 ET Teenagers in England are shunning drink and drugs for a cleaner lifestyle, say health officials. A survey of 6,500 children aged between 11 and 15 showed the numbers taking drugs, smoking and drinking alcohol had all fallen over the past decade. The NHS Health and Social Care Information Centre figures found 17% had tried drugs at least once in 2011, compared with 29% in 2001. The team said youngsters appeared to be living increasingly healthy lifestyles. The survey, which questions a selection of children at English secondary schools, is carried out every year to monitor reported use of drugs, alcohol and cigarettes. The latest poll, carried out between September and December last year, found the number of children at each age who said they had taken drugs in the preceding 12 months was down. Among 15-year-olds, the number fell from 39% in 2001 to 23% in 2011. Only 3% of 11-year-olds had taken drugs. Cannabis was the most commonly used drug, although its was also down. Link: Fewer teens using illegal drugs … Continue reading →

Posted in Drugs | Comments Off on Fewer teens using illegal drugs

Buy Clomid Online Pharmacy

Posted: Published on July 26th, 2012

Por LAURA N. PEREZ SANCHEZ GUAYNABO (AP) - La Autoridad de Desperdicios Slidos (ADS) abrir una convocatoria para establecer en Aguadilla la primera planta de conversin de desperdicios slidos a energa de la Isla. Javier Quintana, director ejecutivo de la ADS, indic que la agencia no favorece ninguna tecnologa en especfico. "Vamos a darle la oportunidad a todas esas tecnologas a que vengan a Puerto Rico para ver cul es la mejor opcin", sostuvo en conferencia de prensa. La apertura de esta planta forma parte de un plan integral de la ADS para atender el problema del manejo de desperdicios slidos en la Isla y coincide con el plan de cierre de vertedero de Aguadilla, uno de los ms importantes del rea noroeste. Tanto el vertedero de Aguadilla como los de Vega Baja, Florida y Santa Isabel se encuentran en proceso de cierre por orden de la Agencia federal de Proteccin Ambiental (EPA, en ingls). El administrador regional de la EPA, Alan Steinberg, anunci un acuerdo preliminar con el municipio de Toa Baja y la empresa que maneja el vertedero de ese municipio _que recibe el 15% de los desperdicios del pas_ para cerrarlo en el 2010. Quintana, por su … Continue reading →

Posted in Online Pharmacy | Comments Off on Buy Clomid Online Pharmacy

Pharmacy school seen as perfect Rx for many

Posted: Published on July 26th, 2012

David Bickel, a 1964 graduate, came out to see Manchester Universitys new pharmacy school Wednesday. He and his wife walked slowly through the large, well-lit hallways before entering the schools auditorium, where Bickel, 73, scanned rows of 150 rising chairs. Its so steep! he said. But theyre young people! quipped back his wife, Evelyn. The Bickels were among dozens of people who came to Manchesters open house for its new School of Pharmacy. The event drew current and prospective students as well as curious members of the public who wanted a peek at the $20 million, 80,000-square-foot building. The Manchester University pharmacy school will open for classes Aug. 13. About 70 students are enrolled and were chosen out of 470 applicants. Forty percent hail from Indiana, while the rest come from across the country. The student body will be 54 percent white and 60 percent female, according to university officials. During the open house, visitors walked through classrooms, office spaces and research and communication labs. They could also tour the auditorium, conference rooms and meeting rooms, which university officials plan to make available to the public. On the left side of the schools main entrance, visitors could peek inside an … Continue reading →

Posted in Pharmacy | Comments Off on Pharmacy school seen as perfect Rx for many

ImmunoCellular Therapeutics Announces Clearance of IND Application for Phase I Study of Company’s Second Vaccine …

Posted: Published on July 26th, 2012

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics (NYSE MKT: IMUC) today announced that the U.S. Food and Drug Administration (FDA) has given clearance to a physician sponsored investigative new drug (IND) application to initiate a Phase I clinical trial of ICT-121, IMUCs novel dendritic-cell-based vaccine targeting CD-133, an antigen that is highly expressed by multiple solid tumors. The trial, which will be conducted at a leading Los Angeles based medical center, will initially test the vaccine in up to 20 patients with recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. With a Phase II trial of IMUCs lead product candidate ICT-107 well under way in treating patients with newly diagnosed GBM, ICT-121 is the Companys second dendritic-cell-based vaccine to enter the clinic. Like ICT-107, ICT-121 targets the cancer stem cells (CSCs) that are widely believed to be the root cause of many cancers. Preclinical studies conducted by IMUC indicate that ICT-121 effectively targets CD-133, a protein that is over-expressed by a very wide range of solid tumors, including glioblastoma, pancreatic, breast, non-small-cell lung cancer, and several other malignancies associated with poor survival and limited treatment options, said Manish Singh, Ph.D., president and CEO of IMUC. Given the … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on ImmunoCellular Therapeutics Announces Clearance of IND Application for Phase I Study of Company’s Second Vaccine …

Ruling frees FDA to crack down on stem cell clinics

Posted: Published on July 26th, 2012

Peter Aldhous, San Francisco bureau chief It's official: stem cells are drugs. At least, that's the opinion of the US district court in Washington DC, which has ruled that the Food and Drug Administration (FDA) has the authority to regulate clinics offering controversial stem cell therapies. Treatments in which stem cells are harvested from bone marrow and injected straight back into the same patient are deemed part of routine medical practice - not regulated by the US government. But if the cells are subjected to more than "minimal manipulation", the FDA maintains that the therapy becomes a "drug", which must be specifically approved for use. It was on this basis that in 2008 the FDA began moves to shut downRegenerative Sciences, a clinic in Broomfield, Colorado, that treats orthopaedic problems using a stem cell therapy called Regenexx. Regenerative Sciences challenged the FDA's authority to regulate its activities, setting the stage for a legal fight. In 2010, the FDA sought an injunction to take Regenexx off the market. This has now been granted in the court's ruling. Christopher Centeno, medical director of Regenerative Sciences, vows to appeal. "This is really round one," he says. "Our position remains that a patient's cells … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Ruling frees FDA to crack down on stem cell clinics

Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial

Posted: Published on July 26th, 2012

ROCKVILLE, Md., July 25, 2012 /PRNewswire/ --Neuralstem, Inc. (NYSE MKT: CUR) announced that the seventeenth patient was treated in the ongoing Phase I trial of its spinal cord neural stem cells for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). This patient is also the second to return to the trial for additional injections. In this treatment, the patient received five injections in the cervical (upper back) region of the spinal cord, in addition to the ten he had previously received in the lumbar (lower back) region, for a total of 15 injections. The final previously treated patient of this cervical cohort is expected to return to the trial in August, provided the inclusion requirements continue to be met. This ground-breaking stem cell trial is taking place at Emory University Hospital in Atlanta, Georgia. (Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO ) "We are pleased that this phase of the trial, in which we have been permitted by the FDA to take the unprecedented step of dosing patients for the second time, is progressing as planned," said Karl Johe, PhD, Neuralstem's Chairman and Chief Scientific Officer. "These are the first patients in the world to receive our cells in both the lumbar … Continue reading →

Comments Off on Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial

Rapamycin Effective in Mouse Model of Inherited Heart Disease and Rare Muscular Dystrophies

Posted: Published on July 26th, 2012

Newswise Rapamycin, an immunosuppressant drug used in a variety of disease indications and under study in aging research labs around the world, improved function and extended survival in mice suffering from a genetic mutation which leads to dilated cardiomyopathy (DCM) and rare muscular dystrophies in humans. There are currently no effective treatment for the diseases, which include Emery-Dreifuss Muscular Dystrophy and Limb-Girdle Muscular Dystrophy. The familial form of DCM often leads to sudden heart failure and death when those affected reach their 40s and 50s. In research published in the July 25, 2012 online edition of Science Translational Medicine, scientists from the Buck Institute and other organizations focused on mutations in the gene LMNA, which produces A-type lamins. Mutations in this gene are associated with at least 13 diseases, with DCM among the most common. DCM accounts for 60 percent of all cardiomyopathy cases. LMNA mutations may account for up to one-third of patients that are diagnosed as having DCM and conduction disease. DCM causes a thinning of the left ventricle and loss of cardiac function. The study showed that deletion of the LMNA gene led to ramped up activity in the molecular pathway mTOR (mammalian target of rapamycin) and … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Rapamycin Effective in Mouse Model of Inherited Heart Disease and Rare Muscular Dystrophies

Rapamycin effective in mouse model of inherited heart disease and muscular dystrophies

Posted: Published on July 26th, 2012

Public release date: 25-Jul-2012 [ | E-mail | Share ] Contact: Kris Rebillot krebillot@buckinstitute.org 415-209-2080 Buck Institute for Age Research Rapamycin, an immunosuppressant drug used in a variety of disease indications and under study in aging research labs around the world, improved function and extended survival in mice suffering from a genetic mutation which leads to dilated cardiomyopathy (DCM) and rare muscular dystrophies in humans. There are currently no effective treatment for the diseases, which include Emery-Dreifuss Muscular Dystrophy and Limb-Girdle Muscular Dystrophy. The familial form of DCM often leads to sudden heart failure and death when those affected reach their 40's and 50's. In research published in the July 25, 2012 online edition of Science Translational Medicine, scientists from the Buck Institute and other organizations focused on mutations in the gene LMNA, which produces A-type lamins. Mutations in this gene are associated with at least 13 diseases, with DCM among the most common. DCM accounts for 60 percent of all cardiomyopathy cases. LMNA mutations may account for up to one-third of patients that are diagnosed as having DCM and conduction disease. DCM causes a thinning of the left ventricle and loss of cardiac function. The study showed that deletion … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Rapamycin effective in mouse model of inherited heart disease and muscular dystrophies

Page 6,651«..1020..6,6506,6516,6526,653..6,6606,670..»